Our goal is to transform chronic inflammatory diseases, many of which are poorly managed by existing treatments that only provide symptom relief, at best.
We have a clinical-stage pipeline of potential therapies for patients with a range of chronic heart and metabolic diseases.
Our research team uses a multi-disciplinary approach to identify and target specific alterations that drive the growth and progression of cancer.
We are tackling some of the most deadly adult and adolescent infectious diseases as well as evaluating therapeutic vaccines for chronic diseases and conditions.
Neurologic and psychiatric diseases are some of the most devastating disorders of our time, causing significant disability around the world.
Rare Diseases are defined by the Orphan Drug Act of 1983 as those diseases affecting fewer than 200,000 patients in the United States.